Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,946
  • Shares Outstanding, K 83,067
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -62,420 K
  • EBIT $ -67 M
  • EBITDA $ -67 M
  • 60-Month Beta 0.10
  • Price/Sales 25.89
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.95
  • Most Recent Earnings $-0.22 on 12/19/25
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 248.42% (-570.23%)
  • Historical Volatility 92.41%
  • IV Percentile 62%
  • IV Rank 22.54%
  • IV High 818.65% on 02/27/26
  • IV Low 82.45% on 02/06/26
  • Expected Move (DTE 18) 0.1530 (36.26%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 44
  • Volume Avg (30-Day) 189
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 13,526
  • Open Int (30-Day) 23,049
  • Expected Range 0.2690 to 0.5750

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.26
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +57.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3801 +11.02%
on 02/06/26
0.5250 -19.62%
on 02/13/26
-0.0180 (-4.09%)
since 02/02/26
3-Month
0.3801 +11.02%
on 02/06/26
2.5375 -83.37%
on 12/17/25
-1.4080 (-76.94%)
since 12/02/25
52-Week
0.3801 +11.02%
on 02/06/26
3.3900 -87.55%
on 08/26/25
-1.0780 (-71.87%)
since 02/28/25

Most Recent Stories

More News
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™...

OTLK : 0.4220 (+0.31%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026 Additional European launches expected in 2026 Type A meeting...

OTLK : 0.4220 (+0.31%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.4220 (+0.31%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.4220 (+0.31%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.4220 (+0.31%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces New Employment Inducement Grants

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.4220 (+0.31%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.4220 (+0.31%)
OTLKW : 0.03 (-1.96%)
Micron Dominates Barchart's Top 100 with Killer Volume—Your Buy Signal?

In Monday’s trading, Micron Technology jumped 14 spots in Barchart’s Top 100 Stocks to Buy, into 36th position. Of the top 100, Micron’s price volume was the highest at 6.53 million, nearly four...

IREN : 41.39 (+1.07%)
OTLK : 0.4220 (+0.31%)
NVDA : 182.48 (+2.99%)
MU : 412.67 (+0.07%)
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.4220 (+0.31%)
OTLKW : 0.03 (-1.96%)

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

3rd Resistance Point 0.4740
2nd Resistance Point 0.4588
1st Resistance Point 0.4404
Last Price 0.4220
1st Support Level 0.4068
2nd Support Level 0.3916
3rd Support Level 0.3732

See More

52-Week High 3.3900
Fibonacci 61.8% 2.2402
Fibonacci 50% 1.8851
Fibonacci 38.2% 1.5299
Last Price 0.4220
52-Week Low 0.3801

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar